Gardovskis, J.
202  Ergebnisse:
Personensuche X
?
 
?
 
?
6

A novel frequent BRCA1 recurrent variant c.5117G > A (p.Gly..:

Loza, P. ; Irmejs, A. ; Daneberga, Z....
Hereditary Cancer in Clinical Practice.  19 (2021)  1 - p. , 2021
 
?
 
?
8

Bladder cancer incidence and mortality trends in Latvia: 19..:

Bitina-Barlote, E. ; Plonis, J. ; Cauce, V....
European Urology Supplements.  18 (2019)  3 - p. e2501-e2502 , 2019
 
?
9

Bladder cancer 5-year survival trends in Latvia: 1996-2017:

Bitina-Barlote, E. ; Plonis, J. ; Cauce, V....
European Urology Supplements.  18 (2019)  3 - p. e2498-e2499 , 2019
 
?
10

High frequency of pathogenic non-founder germline mutations..:

Maksimenko, J. ; Irmejs, A. ; Trofimovičs, G....
Hereditary Cancer in Clinical Practice.  16 (2018)  1 - p. , 2018
 
?
11

Efficacy and safety of delafloxacin compared with vancomyci..:

Pullman, J ; Gardovskis, J ; Farley, B...
Journal of Antimicrobial Chemotherapy.  72 (2017)  12 - p. 3471-3480 , 2017
 
?
12

Detection of allelic variants of the POLE and POLD1 genes i..:

Pätzold, LA ; Bērziņa, D ; Daneberga, Z..
Balkan Journal of Medical Genetics.  20 (2017)  2 - p. 83-87 , 2017
 
?
13

28 Survival rates of hereditary and sporadic prostate cance..:

Plonis, J. ; Malevskis, A. ; Miculis, K....
European Urology Supplements.  14 (2015)  3 - p. e1124 , 2015
 
?
14

The CHEK2 del5395 is a founder mutation without direct effe..:

Plonis, J ; Kalniete, D ; Nakazawa-Miklasevica, M...
Balkan Journal of Medical Genetics.  18 (2015)  2 - p. 33-36 , 2015
 
?
15

29 CHEK2 del5395 is a founder mutation with no direct effec..:

Plonis, J. ; Malevskis, A. ; Miculis, K....
European Urology Supplements.  14 (2015)  3 - p. e1125 , 2015
 
1-15